Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
51,74 USD | +0,17% | -1,86% | -17,60% |
24/04 | INCYTE CORPORATION : Een koopadvies van Oppenheimer | ZM |
23/04 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
Vakgebied
- productverkoop (85,6%);
- royalty's (14,2%);
- inkomsten uit onderzoeks- en samenwerkingsovereenkomsten (0,2%).
Aantal werknemers: 2 524
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Proprietary Therapeutics
100,0
%
| 3 395 | 100,0 % | 3 696 | 100,0 % | +8,87% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
95,1
%
| 3 200 | 95,6 % | 3 500 | 95,1 % | +9,38% |
Europe and Japan
4,9
%
| - | - | 179 | 4,9 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 13-01-14 |
Director of Finance/CFO | 53 | 11-02-19 | |
Pablo Cagnoni
PSD | President | 60 | 05-06-23 |
Steven Stein
CTO | Chief Tech/Sci/R&D Officer | 57 | 02-03-15 |
Investor Relations Contact | - | 01-09-23 | |
Sheila Denton
LAW | General Counsel | 58 | 01-10-23 |
Thomas Tray
AUD | Comptroller/Controller/Auditor | 46 | 01-06-05 |
Peter Langmuir
PRN | Corporate Officer/Principal | - | 01-08-15 |
Corporate Officer/Principal | - | 01-01-16 | |
Vijay Iyengar
PRN | Corporate Officer/Principal | 51 | 01-05-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 01-01-01 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 16-12-19 |
Director/Board Member | 70 | 20-01-15 | |
Otis Brawley
BRD | Director/Board Member | 64 | 27-09-21 |
Jacqualyn Fouse
BRD | Director/Board Member | 62 | 14-11-17 |
Paul Clancy
BRD | Director/Board Member | 62 | 20-01-15 |
Director/Board Member | 57 | 01-10-22 | |
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 13-01-14 |
Katherine High
BRD | Director/Board Member | 72 | 25-03-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 224 526 128 | 220 960 599 ( 98,41 %) | 0 | 98,41 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
MERUS N.V. 6.92% | 4 004 544 | 6.92% | 180 324 616 $ |
Bedrijfsgegevens
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-17,60% | 11,6 mld. | |
-2,86% | 87,37 mld. | |
+3,95% | 41,01 mld. | |
-21,94% | 28,08 mld. | |
+53,11% | 24,72 mld. | |
-5,41% | 17,47 mld. | |
-44,23% | 11,69 mld. | |
-13,96% | 11,56 mld. | |
-0,22% | 8,44 mld. | |
+2,09% | 7,72 mld. |
- Beurs
- Aandelen
- Koers INCY
- Onderneming Incyte Corporation